Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Skin & Wound Healing

From clinic to couch: a pilot study of home-use photobiomodulation for radiation-induced oral mucositis and dermatitis

Self-administered, home-use PBM is a feasible and well-tolerated approach that shows promise as pre-emptive treatment for RT induced OM and RD.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors report a single-arm pilot study of 17 analyzed head and neck cancer patients who self-applied a home near-infrared photobiomodulation device during radiotherapy. Compliance was 60% of expected sessions, and severe oral mucositis and dermatitis were less frequent than the authors expected, though they note larger randomized, placebo-controlled trials are needed.

Participants
17
Who or what was studied
Patients with head and neck cancer scheduled for intensity-modulated radiotherapy with or without concurrent chemotherapy
Limits stated in the abstract
Small single-arm pilot design without a control group, and the authors state that larger randomized placebo-controlled trials are needed to confirm the findings.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Purpose

Radiation-induced oral mucositis (OM) and dermatitis (RD) are common debilitating toxicities of radiotherapy (RT) for head and neck cancer (HNC) patients. While photobiomodulation (PBM) has shown promise in reducing severity of these adverse effects, in-clinic treatments pose logistic and financial challenges. This study assessed the feasibility and compliance of a home-use, self-applied near-infrared PBM device for the prevention and treatment of RT-induced OM and RD.

Methods

This prospective, single-arm trial enrolled 20 HNC patients scheduled for intensity-modulated RT (IMRT) with or without concurrent chemotherapy. Seventeen patients were analyzed following exclusions. Participants self-administered PBM at home twice daily for 9-11 weeks, from RT initiation to four weeks post-RT. The primary outcome was compliance (≥ 50% of expected treatments). Secondary outcomes included incidence of severe (grade 3-4) OM and RD.

Results

67% of the participants completed at least 50% of the prescribed PBM treatments. Overall, 60% of expected sessions were administered, surpassing the predefined compliance threshold. By week 3, 6% presented with severe OM and none with severe RD. At RT completion, 41% and 18% had severe OM and RD, respectively. Four weeks post-RT, no severe OM or RD were observed, with the majority presenting with no toxicity (grade 0). No device related adverse effects were reported, and patients reported high comfort and ease of use.

Conclusion

Self-administered, home-use PBM is a feasible and well-tolerated approach that shows promise as pre-emptive treatment for RT induced OM and RD. Large-scale, randomized, placebo-controlled trials are needed to confirm these findings and evaluate long-term benefits.

Trial Registration

ClinicalTrials.gov Identifier: NCT05176834.

Registration Date

December 13th, 2021.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a trial: what to check before relying on this kind of research.

Terms in this paper: Photobiomodulation, Oral mucositis, Pilot study, GRADE, Placebo-controlled, Trial registration, Primary outcome, Near-infrared. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies